Related Experiment Video
Updated: Aug 9, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
Genetic association between COPD and polymorphisms in TNF, ADRB2 and EPHX1
J Brøgger1, V M Steen, H G Eiken
1Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, Helse Bergen HF, Jonas Liesv. 65, Bergen N-5021, Norway. jan.brogger@med.uib.no
The European Respiratory Journal
|April 6, 2006
Summary
Genetic variations in microsomal epoxide hydroxylase (EPHX1) may protect against chronic obstructive pulmonary disease (COPD). A meta-analysis confirmed a protective effect for the EPHX1 Tyr113His polymorphism in smokers.
Area of Science:
- Genetics
- Pulmonology
- Environmental Health
Background:
- Chronic obstructive pulmonary disease (COPD) has a known hereditary component.
- Identifying genetic susceptibility factors for COPD is crucial for understanding disease etiology.
- Previous studies have investigated various candidate genes, including EPHX1, TNF, and ADRB2.
Purpose of the Study:
- To investigate the association between specific gene polymorphisms and COPD risk in Caucasian smokers.
- To conduct a meta-analysis to consolidate evidence on the role of EPHX1, TNF, and ADRB2 polymorphisms in COPD.
- To identify potential genetic markers for COPD susceptibility.
Main Methods:
- A case-control genetic association study was performed on 492 Caucasian smokers and former smokers.
- A meta-analysis was conducted, incorporating 16 previous studies.
- Seven polymorphisms in three genes (EPHX1, TNF, ADRB2) were analyzed.
Main Results:
- The EPHX1 Tyr113His polymorphism demonstrated a protective effect against COPD (homozygous OR = 0.5).
- The meta-analysis confirmed this protective association for EPHX1 Tyr113His homozygotes (pooled OR = 0.5).
- Other candidate single nucleotide polymorphisms (SNPs) showed weak or insignificant associations, with concerns about genotyping accuracy.
Conclusions:
- The findings support a significant role for microsomal epoxide hydroxylase (EPHX1) in the development of chronic obstructive pulmonary disease.
- The EPHX1 Tyr113His polymorphism may confer protection against COPD in smokers.
- Further research is warranted to elucidate the precise mechanisms by which EPHX1 influences COPD pathogenesis.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:23Chronic Obstructive Pulmonary Disease I: Introduction
Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
01:20Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
01:20COPD: Pathogenesis and Clinical Features
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...